جستجوی مقالات مرتبط با کلیدواژه "prednisone" در نشریات گروه "پزشکی"

 In recent years, the incidence of pediatric nephrotic syndrome (NS) has been increasing, and timely and effective treatment is critical to protect the health of children with NS. This study is an attempt to compare the therapeutic effects of prednisone  (Pred) plus dipyridamole (DIP) versus Pred plus valsartan (VAL)on pediatric NS.

 Two hundred pediatric cases of NS were selected as the research participants, including 109 cases (group A) receiving Pred + DIP and 91 cases (group B) receiving Pred + VAL. The clinical
efficacy, adverse reactions, and renal, coagulation functions and blood lipid levels, as well as the pre- and post-treatment levels of inflammatory factors (IFs) and immunoglobulins (Igs) were
comparatively analyzed.

No statistically significant differences were found between groups in terms of clinical efficacy, incidence of adverse reactions and renal function (P > .05). After receiving the corresponding treatment, group A showed better coagulation and immune functions than group B, but higher levels of IFs and poorer blood lipid function (P < .05).

 Both Pred + DIP and Pred + VAL combination therapies can be used for the treatment of pediatric NS, with the former contributing to more obviously enhanced coagulation and immune functions, and the latter leading to more significantly inhibited inflammation and better regulated blood lipid function.

This study aimed to explore the effect of prednisone (PDN) combined with cyclophosphamide (CTX) on bleomycin-induced pulmonary fibrosis (PF) in rats via circular RNA mortality factor 4 like 1 (MORF4L1)/microRNA (miR)-29a-3p/Bromodomain protein 4 (BRD4) axis. A rat model of PF was induced by bleomycin and treated with PDN combined with CTX, and the lentiviral vectors that interfered with MORF4L1, miR-29a-3p, or BRD4 expression were injected into the tail vein at the same time. The mRNA expressions of MORF4L1, miR-29a-3p, BRD4, and fibrosis-associated proteins including fibronectin, connective tissue growth factor, and collagen I were detected by real-time quantitative polymerase chain reaction. The expression level of BRD4 protein in rat lungs was detected by Western blot analysis. Lung pathology of rats was observed by hematoxylin and eosin and Masson’s trichrome staining. Apoptosis was observed by terminal deoxynucleotidyl transferase dUTP nick end labeling staining. The targeting relationship between miR-29a-3p and MORF4L1 or BRD4 was verified by the bioinformatics website and dual luciferase reporter experiment. Bleomycin-induced PF enhanced MORF4L1 and BRD4 expression, inhibited miR-29a-3p expression, injured lung tissue, increased mRNA expression of fibrosis-related markers, and induced apoptosis in the lung tissue of rats. PDN combined with CTX had a therapeutic effect on PF in rats, which was further promoted by down-regulating MORF4L1 or up-regulating miR-29a-3p. After down-regulating miR-29a-3p or up-regulating BRD4, the effect of down-regulating MORF4L1 was reversed. MORF4L1 could bind to miR-29a-3p to target BRD4. In short, PDN combined with CTX can effectively improve PF through downregulating MORF4L1 to enhance miR-29a-3p-targeted regulation of BRD4.

Nephrotic syndrome is a clinical manifestation of glomerular  disease characterized by severe or nephrotic-range proteinuria >3.5 g/24 hours. The treatment of nephrotic syndrome using corticosteroid especially prednisone, belongs to a class of glucocorticoid. Glucocorticoids are proven  to be  able to inhibit growth through several mechanisms.  The objective of this study  was  to  analyze  the  characteristic  of  height  in  childhood  nephrotic syndrome  and  analyze  the  correlation  between corticosteroid therapy and height in childhood nephrotic syndrome.

 This systematic review was conducted using the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA)  guideline.  The  literature  search  was  conducted  in  November  2020  in  four  databases:  PubMed,  Science  Direct, Scopus, and DOAJ. Quality assessment was carried out using a quality assessment tool for quantitative studies from EPHPP.

Six studies met the inclusion criteria for final analysis.  The mean final height z-scores were -0.66 ± 3.04. The height z-scores of Steroid-Dependent Nephrotic Syndrome (SDNS) (-0.33 ± 0.87) and Steroid-Resistant Nephrotic Syndrome (SRNS) (-0.97  ±  1.34)  patients  were  lower  than  Steroid-Sensitive  Nephrotic  Syndrome  (SSNS)  (-0.20  ±  3.14)  patients.  The height  zscores of nephrotic syndrome children were significantly lower than a normal population.  Five studies suggested that there is a correlation  between  corticosteroid  therapy  and  height  on  childhood  nephrotic syndrome  and  one  study  did  not  find  a correlation between them.

 According  to  findings,  there  is  a  negative  correlation  between  corticosteroid  therapy  and  height  in childhood nephrotic syndrome. Nephrotic syndrome children had significantly lower height z-scores than a normal population. The SDNS and  SRNS  patients  are  more  susceptible  to  have  a  lower  height  than  SNSS  patients  as  they  have  a  higher  cumulative corticosteroid dose.

The aim of this study was to evaluate and compare the therapeutic efficacy of subcutaneous enoxaparin versus oral prednisone (as a standard treatment) in patients with disseminated lichen planus.

In this parallel randomized clinical trial study, overall 48 patients completed the study. 25 patients were treated with subcutaneous enoxaparin 5 mg weekly and 23 patients with 0.5 mg/kg prednisone orally daily until complete remission or a maximum of 8 weeks. The results of itching severity, extent of active lesions and drug side effects were compared. In remission, patients were followed for 6 months for recurrent lesions.

In enoxaparin group, 8 patients (32%) had complete remission and 10 patients (40%) had partial improvement. In the oral prednisone group, 16 patients (69.6%) had complete remission and 6 patients (26.1%) had partial improvement (P = 0.005). Average size of active lesions in both groups decreased significantly after treatment, but analysis of covariance showed that the mean lesion size after treatment in the oral prednisone group was significantly lower than the enoxaparin group (P = 0.005). The relapse rate from improved patients in the enoxaparin group was 6 (33%) and in oral prednisone group was 9 (40.9%, P = 0.083). In the enoxaparin group no serious complications was seen. But 22% in the oral prednisone group show side effect, the most common complications were dyspepsia.

Low dose enoxaparin on lichen Planus have therapeutic effect and is important for the least side effects but not as much as oral prednisone. But it could be accepted as an alternative treatment.

Steroids are commonly used in the treatment of cervical radiculopathy (CR), but there is limited information in this regard. We evaluated the efficacy of oral prednisone in the treatment of CR. This randomized, double-blinded, placebo-controlled trial was conducted on adult patients with neck/shoulder pain for at least 1 month with no alarm symptoms/sings of malignancy, infection, or severe myelopathy, and no contraindication for corticosteroid use. Patients were allocated to receive prednisolone 50 mg/day for 5 days that was tapered within the following 5 days, or placebo. All patients also received acetaminophen 325 mg three times a day and ranitidine 150 mg two times a day. Neck disability index (NDI) and the verbal rating scale (VRS) were used to evaluate the outcomes. A total of 59 patients (31 female, mean ± SD age = 46.2±9.0 years) completed the study. A significant decrease was observed regarding the NDI and VAS scores from baseline to the end of study in both groups (P < 0.001). However, for both the NDI (35.7±21.4 vs. 12.9±10.2) and VRS (4.4±2.7 vs. 1.6±1.2), the amount of decrease was greater in the prednisone compared with the placebo group (P < 0.001). Based on the clinically important change in NDI, pain was improved in 75.8% (22/29) of the prednisolone and 30% (9/30) of the placebo group (P < 0.001). A short course of oral steroid therapy with prednisolone is highly effective in reducing pain in patients referring with uncomplicated CR. Further studies are warranted on dosing, duration, and long-term efficacy and safety of oral steroid therapy, compared with injection approach.